AHA March 26 submitted comments on a discussion draft of the SUSTAIN 340B Act, legislation proposed in the Senate to clarify Congress’ intent in creating the 340B program and protect 340B providers from egregious behavior by drug companies, insurers and pharmacy benefit managers.  

“Their unlawful and pernicious practices have collectively undermined the 340B program and harmed patient care,” AHA wrote. “At the same time, we have concerns regarding other aspects of this discussion draft that should be better aligned to reflect the operational realities that 340B hospitals face every day. Therefore, our comments primarily focus on how Congress can ensure that the 340B program continues to benefit patients and communities, while protecting against any unnecessary harm or burden that would jeopardize patient care.” 

Related News Articles

Headline
Stacey Hughes, AHA’s executive vice president for government relations and public policy, discussed key messages that hospital and health system leaders should…
Headline
President Biden March 24 signed legislation funding the rest of the federal government through Sept. 30, including Department of Health and Human Services…
Headline
The House and Senate Appropriations committees March 20 released the Further Consolidated Appropriations Act of 2024, legislation that would fund all remaining…
Headline
The House Energy and Commerce Committee March 20 unanimously passed AHA-supported legislation to reauthorize through 2029 the Dr. Lorna Breen Health Care…
Headline
The House Energy and Commerce Health Subcommittee March 12 passed AHA-supported  legislation to reauthorize through 2029 the Dr. Lorna Breen Health Care…
Headline
AHA March 12 released a new report from Healthsperien on discounts to 340B hospitals through the 340B Drug Pricing Program relative to drug company revenues…